Source:http://linkedlifedata.com/resource/pubmed/id/18778086
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
20
|
pubmed:dateCreated |
2008-10-15
|
pubmed:abstractText |
Many drugs and chemicals exert their biological effect by modulating protein-protein interactions. In vitro approaches to characterize these mechanisms are often based on indirect measurements (e.g., fluorescence). Here, we used mass spectrometry (MS) to directly monitor the effect of small-molecule ligands on the binding of a coactivator peptide (SRC1) by the human estrogen receptor alpha ligand binding domain (hERalpha LBD). Nanoelectrospray mass spectrometry (nanoESI-MS) and high-mass matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) combined with chemical cross-linking were employed to follow these processes. The chemical cross-linking protocol used prior to high-mass MALDI analysis allows detection of intact noncovalent complexes. The binding of intact hERalpha LBD homodimer with two coactivator peptides was detected with nanoESI-MS and high-mass MALDI-MS only in the presence of an agonist ligand. Furthermore, high-mass MALDI-MS revealed an increase of the homodimer abundance after incubating the receptor with a ligand, independent of the ligand character (i.e., agonist, antagonist). The binding characteristics of the compounds tested by MS correlate very well with their biological activity reported by cell-based assays. High-mass MALDI appears to be an efficient and simple tool for directly monitoring ligand regulation mechanisms involved in protein-protein interactions. Furthermore, the combination of both MS methods allows identifying and characterizing endocrine-disrupting compounds or new drug compounds in an efficient way.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
1520-6882
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:day |
15
|
pubmed:volume |
80
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
7833-9
|
pubmed:meshHeading |
pubmed-meshheading:18778086-Amino Acid Sequence,
pubmed-meshheading:18778086-Dimerization,
pubmed-meshheading:18778086-Endocrine Disruptors,
pubmed-meshheading:18778086-Estrogen Receptor alpha,
pubmed-meshheading:18778086-Humans,
pubmed-meshheading:18778086-Ligands,
pubmed-meshheading:18778086-Mass Spectrometry,
pubmed-meshheading:18778086-Peptides,
pubmed-meshheading:18778086-Pharmacology,
pubmed-meshheading:18778086-Protein Binding,
pubmed-meshheading:18778086-Protein Structure, Quaternary,
pubmed-meshheading:18778086-Protein Structure, Tertiary
|
pubmed:year |
2008
|
pubmed:articleTitle |
Monitoring ligand modulation of protein-protein interactions by mass spectrometry: estrogen receptor alpha-SRC1.
|
pubmed:affiliation |
Department of Chemistry and Applied Biosciences, ETH Zurich, 8093 Zurich, Switzerland.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|